Case report: Fulminant type 1 diabetes following paucisymptomatic SARS-CoV-2 infection during late pregnancy

Front Endocrinol (Lausanne). 2023 Apr 4:14:1168927. doi: 10.3389/fendo.2023.1168927. eCollection 2023.

Abstract

Background: Dysregulation of glucose metabolism has been linked to SARS-CoV-2 infection. In addition, the occurrence of new onset diabetes mellitus, including fulminant type 1 diabetes, has been reported after SARS-CoV-2 infection or vaccination.

Methods and results: A young Chinese woman in her last trimester of pregnancy presented with an abrupt progression of hyperglycemia and ketoacidosis, but with a near-normal glycohemoglobin level following paucisymptomatic SARS-CoV-2 infection. The low C peptide levels, both fasting and postprandial, reflected profound insulin deficiency in the setting of negative islet autoantibody testing, consistent with a diagnosis of fulminant type 1 diabetes. Ketoacidosis and hyperglycemia quickly improved following the introduction of insulin therapy, but not the β cell function. The patient received treatment with insulin pump therapy after being discharged, and the first follow-up revealed a well-controlled glucose profile.

Conclusions: New-onset FT1D can occur after SARS-CoV-2 infection. Our report raises awareness of this rare but serious situation, promoting early recognition and management of FT1D during the COVID-19 pandemic.

Keywords: case report; coronavirus disease 2019 (COVID- 19); fulminant type 1 diabetes; pregnancy; severe acute respiratory syndrome coronavirus 2.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • COVID-19* / complications
  • Diabetes Mellitus, Type 1*
  • Female
  • Humans
  • Hyperglycemia*
  • Insulin / metabolism
  • Ketosis*
  • Pandemics
  • Pregnancy
  • SARS-CoV-2 / metabolism

Substances

  • Insulin

Grants and funding

This study was supported by grants from the Medical Health Science and Technology Project of Zhejiang Provincial Health Commission (2023RC234, HQ is the recipient) and the Hangzhou Medical Health Science and Technology Project (A20220027, JH is the recipient).